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Abstract
Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase aberrantly expressed in a variety of tumor types, most
notably in Anaplastic Large Cell Lymphoma (ALCL) where a chromosomal translocation generates the oncogenic fusion
protein, Nucleophosmin-ALK (NPM-ALK). Whilst much is known regarding the mechanism of transformation by NPM-ALK,
the existence of cellular defence pathways to prevent this pathological process has not been investigated. Employing the
highly tractable primary murine embryonic fibroblast (MEF) system we show that cellular transformation is not an inevitable
consequence of NPM-ALK activity but is combated by p53 and Rb. Activation of p53 and/or Rb by NPM-ALK triggers a
potent proliferative block with features reminiscent of senescence. While loss of p53 alone is sufficient to circumvent NPM-
ALK-induced senescence and permit cellular transformation, sole loss of Rb permits continued proliferation but not
transformation due to p53-imposed restraints. Furthermore, NPM-ALK attenuates p53 activity in an Rb and MDM2
dependent manner but this activity is not sufficient to bypass senescence. These data indicate that senescence may
constitute an effective barrier to ALK-induced malignancies that ultimately must be overcome for tumor development.
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Introduction
Anaplastic Lymphoma Kinase (ALK) is a member of the insulin
receptor tyrosine kinase family, whose expression is predominately
limited to the developing nervous system and at low levels in adult
neuronal cells [1,2,3]. Whilst little is known of the physiological
function of ALK, it is rapidly gaining recognition as an important
oncogene in a diverse range of tumor types, including Anaplastic
Large Cell Lymphoma (ALCL), melanoma, breast cancer, non-
small cell lung carcinoma, neuroblastoma, inflammatory myofi-
broblastic tumors and esophageal squamous cell carcinoma
although its involvement in some of these cancers is still somewhat
controversial [1,4,5,6,7,8,9,10,11,12,13,14,15,16]. Deregulated
ALK expression in each of these cases is the consequence of
either activating point mutations of the full-length protein or
chromosomal aberrations including translocations and inversions
which juxtapose the kinase region of ALK to an oligomerization
domain encoded in the partner gene. The oncogenic potential of
ALK has been best demonstrated in ALCL in which it is expressed
as a fusion protein, predominantly juxtaposed to NPM [1]. The
NPM portion of NPM-ALK provides an oligomerization interface
to permit dimerization of NPM-ALK monomers, followed by
autophosphorylation and constitutive activation [17]. A direct role
for NPM-ALK in cellular transformation has been shown both in
vitro and in vivo, and such studies have shed light on the mechanism
of malignant transformation by this oncoprotein [18,19]. These
mechanisms include activation of several downstream signal-
transduction pathways, which regulate cell survival, proliferation
and migration [18,20,21].
The t(2;5) encoding NPM-ALK and the corresponding
transcripts have been detected in the peripheral blood of
apparently healthy individuals at a frequency of 48–65%
[22,23]. These findings are in line with the presence of other
known oncogenic translocations in tumor-free donors, such as
BCR-ABL [24,25], IgH-Bcl2 [26,27] and PML-RARa [28].
These data indicate that the presence of the oncogenic
translocation per se is not sufficient for tumorigenesis; rather,
additional molecular events are likely required for the cell to
become fully transformed and to bypass barriers such as apoptosis
or oncogene-induced senescence (OIS) [29]. Further evidence for
multi-step NPM-ALK-induced lymphomagenesis stems from
studies of NPM-ALK-transgenic mice in which the latency to
disease in some cases can be anything from 9 months to 2 years
suggesting a requirement for cooperative mutations [30,31].
Hence, these findings imply that NPM-ALK is necessary but not
sufficient for lymphoma development.
The p53 and Rb tumor-suppressor genes are two of the most
frequently mutated genes in human cancer, and the proteins
encoded by these genes have multiple tumor-suppressor functions,
not least their roles in apoptosis, transient cell-cycle arrest and
senescence [32]. In order to investigate whether aberrant ALK
activity has the potential to trigger cellular mechanisms that
prevent oncogenic transformation, NPM-ALK was expressed in
primary murine embryonic fibroblasts (MEFs), a genetically
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amenable and well-characterized system that has been used
extensively in the study of oncogene-induced senescence and
apoptosis. Particular attention was paid to the potential roles of
the p53 and Rb pathways in limiting NPM-ALK-induced
transformation.
We show that NPM-ALK induces a cell-cycle arrest with
features characteristic of senescence. We further show that this
senescence-like arrest is dependent on the activity of p53 and Rb,
two tumor-suppressor proteins whose activity is frequently de-
regulated in NPM-ALK+ ALCL [33,34].
Results
NPM-ALK kinase activity induces cell-cycle arrest of
primary MEFs with features of senescence
Early-passage MEFs were transduced by retrovirus with
MSCVpuro vectors encoding NPM-ALK, a kinase-dead mutant
of NPM-ALK (K210R), H-Ras V12 or insert-free vector and were
selected in puromycin for three days before their use in the assays
described below. The timeline of the experiment is depicted in
Figure 1A.
H-Ras V12 is an oncoprotein that induces senescence when
expressed in primary MEFs (Figure 1B and [35]). Likewise, it was
observed that expression of the oncogenic tyrosine kinase NPM-
ALK in MEFs prevented the accumulation of cells as assessed by
crystal violet assay (Figure 1B). The amount of cell death was
similar between control and NPM-ALK-expressing cells (Figure
S1), indicating that the reduced proliferative capacity of the latter
was primarily due to cell-cycle arrest rather than cell death.
Consistent with this notion, cells remained attached to the plates
and DNA synthesis (as measured by BrdU and PI incorporation)
was reduced in NPM-ALK-expressing cells to a level comparable
to that of H-Ras V12-expressing MEFs (Figure 2A). The cell-cycle
arrest was dependent on the kinase activity of NPM-ALK since the
kinase-dead K210R mutant showed the same growth kinetics and
cell-cycle profile as vector control cells (Figures 1B and 2A).
Cell-cycle analysis of both NPM-ALK- and H-Ras V12-
expressing cells revealed a significant decrease in the percentage
of cells with 2n–4n DNA content (indicating S-phase) and an
accumulation of cells with 4n DNA content (indicating G2/M)
(Figure 2A, B). H-Ras V12 expression in primary cells has
previously been associated with an arrest of cells in the G1 phase
of the cell cycle, therefore to determine whether the accumulation
of cells with 4n DNA content was in fact a result of a G1 tetraploid
arrest (DNA synthesis in the absence of cytokinesis) cells were
subjected to microscopic examination and Western blot analysis
for the G2/M marker, cyclin B. At day 4 of the experimental time
frame NPM-ALK- and H-Ras V12-expressing cells containing two
nuclei were present at high frequency in the population (Figure 2B,
right panel and data not shown) and, furthermore, Western blot
analysis revealed that Rb was present in NPM-ALK-expressing
cells predominantly in its hypophosphorylated (active) form
without up-regulation of the G2/M marker cyclin B but with
down-regulation of cyclin A (Figure 2C). Together, these data
support a predominant tetraploid G1 arrest of NPM-ALK-
expressing cells.
Consistent with a senescent arrest NPM-ALK-expressing cells
did not resume proliferation after at least a month of culture (data
not shown), displayed typical morphological features of senescent
cells, becoming enlarged and flattened (Figure 2B, right panel),
and a substantial proportion of the cell population stained
positively for Senescence-Associated-b-Galactosidase (SA-b-Gal)
activity by day 4 of the experimental time-frame (Figure 2D).
NPM-ALK-induced senescence-like arrest is dependent
on p53
H-Ras V12-induced senescence of MEFs requires an intact
p19ARF/p53 pathway [35,36]. To determine if this is likewise the
case for NPM-ALK, we expressed NPM-ALK in p53-deficient
(p532/2) MEFs and assessed growth and SA-b-Gal staining
shortly after retroviral transduction and selection. In the absence
of p53, NPM-ALK-induced growth arrest was bypassed
(Figure 3A) and the cells no longer stained positively for SA-b-
Gal (Figure 3B). In fact, NPM-ALK-expressing p532/2 MEFs lost
contact inhibition, were capable of proliferation at low density and
could grow without a solid support in soft-agarose, all features
consistent with a transformed phenotype (Figure 3C). Despite the
involvement of p53 in NPM-ALK-induced senescence, we did not
observe stabilization of the protein nor induction of its prototypic,
senescence-associated target gene p21 by Western blot analysis,
whereas H-Ras V12 induced both of these proteins at two different
time points (days 1 and 3 of the experimental time-frame;
Figure 4A), consistent with previous observations [35]. We noted
that p19ARF, a protein required to stabilize p53 [37], was induced
to only modest levels compared to H-Ras V12 following NPM-
ALK expression, which may account for the lack of detectable p53
stabilization in these cells (Figure 4A). Moreover, we have
previously reported that NPM-ALK targets p53 for degradation
via the MDM2 and JNK pathways in transformed human ALCL
cell lines [33]. Thus, the lack of p53 stabilization is consistent with
our previous findings. Indeed, treatment of NPM-ALK-expressing
MEFs with the MDM2 inhibitor, nutlin-3, for 1, 2 and 4 hours
was sufficient to stabilize p53 to relatively high levels by 2 hours
post-treatment, leading to the induction of p21 and MDM2
Figure 1. NPM-ALK expression in primary MEFs inhibits cellular
proliferation. (A) Experimental design and reference timeframe.
Infection refers to exposure of MEFs to retrovirus, and selection refers
to enrichment for transduced cells with 2 mg/ml of puromycin. (B) MEFs
infected with retrovirus and selected for expression of the indicated
genes were assessed for their ability to proliferate over 6 days via crystal
violet assay. Relative cell growth was determined by comparing crystal
violet optical density values obtained at 590 nm at each time point with
those obtained at day 0. Each time point was conducted in triplicate in
at least 3 separate experiments using MEFs from independent embryo
preparations. Error bars are standard deviations of the mean.
doi:10.1371/journal.pone.0017854.g001
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(Figure 4B). The return of p53 to basal levels by 4 hours post-
treatment may indicate the activation of alternative p53-
degradation pathways. Treatment of H-Ras V12-expressing cells
in the same manner did not lead to further p53 stabilization nor
enhanced p21 induction, presumably indicating that the MDM2-
p53 interaction is already maximally disrupted in these cells and
also suggesting that NPM-ALK induces expression of p53 whilst
simultaneously enabling its degradation (p53 expression levels are
much higher in the NPM-ALK expressing cells suggesting that it
induces transcription of this protein).
Consistent with a role for p53 in the suppression of cellular
transformation by NPM-ALK, transgenic mice in which NPM-
ALK expression is driven from the lymphoid-specific CD2
promoter [30] exhibited accelerated lymphoma development
and increased tumor incidence when the oncogene was expressed
on a p53 heterozygous genetic background relative to NPM-ALK
expression on a p53 wild-type background (p,0.0005) (Figure 4C).
These data are indicative of a p53-imposed delay in tumorigenesis
induced by NPM-ALK.
In summary, NPM-ALK induces a senescence-like growth
arrest that is dependent on p53 in the absence of further p53
stabilization Alternatively, NPM-ALK induces concomitant tran-
scription and degradation of p53 protein which equilibrate to
levels sufficient for senescence induction.
p16 is dispensable for NPM-ALK-induced senescence
Another major pathway involved in senescence is the p16/Rb
pathway [38]. To address the role of this pathway in NPM-ALK-
induced senescence, NPM-ALK was initially expressed in p16-
deficient (p162/2) MEFs and the expansion of puromycin-selected
cells was assessed by crystal violet assay. We observed that
germline loss of p16 was insufficient to bypass growth arrest
induced by both NPM-ALK and H-Ras V12 (Figure 5A).
Acute mutation of Rb permits bypass of NPM-ALK-
induced senescence but is insufficient for transformation
It has previously been shown that following germline mutation
of Rb, the protein product of which is the downstream target of
p16, the Rb-related proteins p107 and p130 can functionally
compensate in certain cellular contexts [39,40]. Therefore to
determine a direct role for the Rb pathway in NPM-ALK-induced
senescence, NPM-ALK was expressed in conditional Rb-knockout
(cRblox/lox) MEFs in which the Rb gene can be irreversibly ablated
at will via the addition of Adenovirus expressing Cre-recombinase
recognizing LoxP-flanked sequences in exon 3 of the Rb gene
(Figure S2A and [40]). MEFs were infected and selected according
to the protocol shown in Figure S2B. Following passage according
to a standard 3T3 protocol (see materials and methods) we
observed that NPM-ALK-expressing MEFs invariably overcame
any initial growth deficit at early passage and exhibited robust
proliferation for at least two months (Figure 5B). Paradoxically,
Western blot analysis of lysates harvested from 2 independent cell
populations cultured under the same conditions at passage 18 and
15 respectively revealed that both p19ARF and p53 levels were
highly elevated in NPM-ALK-expressing cells (Figure 5C).
Furthermore, p53 was functional in floxed cRblox/lox NPM-ALK-
expressing cells as revealed by the inability of the cells to adopt a
transformed phenotype (loss of contact inhibition and growth in an
anchorage-independent manner) unless p53 function was simul-
taneously disrupted via co-infection with a retrovirus encoding the
p53 dominant-negative peptide, GSE56 (Figure 5D and Table 1).
GSE56 antagonizes p53 function through interaction with its
oligomerisation domain, subsequently resulting in the dramatic
accumulation of inactive p53 [41] (Figure 5D). Thus, Rb
functional loss permits bypass of NPM-ALK-induced senescence
but transformation is nevertheless prevented due to p53-imposed
restraints. This interplay between the p53 and Rb pathways in
senescence bypass and transformation has previously been
described for H-Ras V12 and indicates that p53 can act
downstream of Rb in the prevention of cellular transformation
[40,42].
Rb is required for NPM-ALK-mediated p53 degradation
The data presented in Figure 5C further revealed that in the
absence of Rb, NPM-ALK activity was sufficient to induce p53
(compare lack of p53 induction in NPM-ALK-expressing cells in
wild-type MEFs in Figure 4A and p53 induction in Rb-deficient
MEFs in Figure 5C), suggesting that Rb is required for the
previously described mechanism of NPM-ALK-mediated p53
degradation [33]. This requirement for Rb was also confirmed in
early passage MEFs where p19ARF remained only modestly
induced (Figure 5E), and warrants further investigation.
Discussion
Much work has been performed to delineate the mechanism of
transformation by oncogenic ALK, with most studies focusing on
the activity of NPM-ALK and its role in the genesis of ALCL
[18,19,21]. Carcinogenesis is generally regarded as a multi-step
process requiring an undefined number of mutations and/or
epigenetic changes that confer specific growth advantages and/or
permit bypass of tumor-suppressive mechanisms [29]. Using
primary cell lines we demonstrate here that NPM-ALK triggers
a durable proliferative arrest via activation of the p53 and Rb
pathways with many features characteristic of senescence. These
data indicate that loss of p53 or Rb function permits bypass of
NPM-ALK-induced cell-cycle arrest, with p53 loss-of-function also
leading to transformation. Whilst the p53 gene is rarely mutated in
ALK+ ALCL [43] - indeed p53 mutations are uncommon in a
range of hematopoietic cancers [44] – we have previously shown
that p53 function is disrupted in ALK+ ALCL cell lines through
NPM-ALK-mediated p53 degradation in a manner that depends
on the activities of MDM2 and JNK [33]. We likewise
demonstrate here a dependency on MDM2, as well as Rb, to
Figure 2. NPM-ALK expression in primary MEFs induces a senescence-like arrest. (A) Representative data of flow cytometric cell-cycle
analysis following BrdU incorporation and PI staining. The assay was performed at day 6. Lower-left box identifies cells with 2n DNA content; upper
box identifies cells in S phase; Lower-right box identifies cells with 4n DNA content. (B) Graphical representation of cell-cycle analysis (left panel). Data
shows the mean of three independent experiments. Error bars are standard deviations of the mean. *denotes significance at p,0.05 using a
Student’s T-test. Microscopic examination at6100 magnification showing NPM-ALK cells with 2 nuclei (indicated by arrows) (right panel). (C) Protein
lysates prepared from cells transduced with and selected for expression of vectors encoding NPM-ALK (NA) or an empty vector (EV) were examined
by Western blot for expression of the indicated proteins with their respective antibodies (pp-Rb indicates phosphorylated Rb). (D) Bright-field images
of MEFs (625 magnification) infected with the indicated retroviruses and assayed for SA-b-Gal activity (indicated by blue coloring) at day 4 (right
panel). The bar chart displays quantification of the senescence assay. H-Ras-V12-expressing MEFs were used as a positive control for senescence. At
least 200 cells were counted per well (in triplicate in at least 3 separate experiments using MEFs from independent embryo preparations). Error bars
are standard deviations of the mean. **denotes significance at p,0.01 using a Student’s T-test.
doi:10.1371/journal.pone.0017854.g002
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target p53 for degradation in NPM-ALK-expressing MEFs, albeit
at an insufficient level in this case to disrupt p53 function entirely,
thus triggering growth arrest and preventing transformation.
However, in the context of incipient tumor cells in vivo, it is possible
that other undefined molecular events co-operate with NPM-ALK
to abrogate p53 function (see Figure 6).
The prevention of p53 stabilization and p21 induction following
NPM-ALK expression in MEFs may at first glance appear at odds
with a role for p53 in preventing NPM-ALK-induced senescence.
These data suggest that basal levels of p53 are sufficient to mediate
the growth arrest response. Indeed, p53 exists at low basal levels
under homeostatic conditions to be functionally activated in
Figure 3. NPM-ALK-induced senescence is p53-dependent. Early-passage p532/2 MEFs were retrovirally transduced with empty (EV), NPM-
ALK- (NA), or H-Ras-V12 (Ras)-containing vectors and selected in puromycin as detailed in Fig. 1A before use in the following experiments: (A) Relative
cell growth was determined by comparing crystal violet optical density values obtained at 590 nm at each time point with those obtained at day 0.
(B) SA-b-Gal activity was determined at day 4 post-selection. At least 200 cells were counted per well. (C) Anchorage-independent growth in soft
agarose was assessed by foci formation at weeks 2–3. Each experiment in (A)–(C) was conducted in triplicate in at least 2 separate experiments using
MEFs from independent embryo preparations. Error bars are standard deviations of the mean. **denotes significance at p,0.01 using a Student’s T
test.
doi:10.1371/journal.pone.0017854.g003
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response to cellular stress. This can occur as a result of covalent
modifications that disrupt the C-terminal negative regulatory
domains of p53 tetramers, leading to conformational changes
compatible with DNA binding and transactivation of p53-
responsive genes [45]. Thus, whilst p53 expression was not
detectably increased in response to NPM-ALK activity, there
remains the possibility that the basal levels of p53 present are
transcriptionally active as a consequence of NPM-ALK-induced
post-translational modifications. Furthermore, the repertoire of
p53-responsive genes transcribed may be different to H-Ras-V12-
Figure 4. NPM-ALK-induced senescence is p53-dependent but is not due to protein stabilization. (A) Western blot demonstrating lack of
p53/p21/p16/p19 up-regulation in response to NPM-ALK expression in MEFs at the indicated time points in comparison to oncogenic H-Ras V12-
expressing cells. (B) NPM-ALK-expressing MEFs treated with the MDM2-antagonist Nutlin-3 for the indicated times show stabilization of p53 and
transcriptional activity as evidenced by p21 expression, detected by Western blot. (C) CD2/NPM-ALK transgenic mice when back-crossed onto a p53
heterozygous background displayed a significant increase in tumor development suggesting that p53 delays tumor progression.
doi:10.1371/journal.pone.0017854.g004
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Figure 5. Acute mutation of Rb (but not germline loss of p16) permits escape from NPM-ALK-induced senescence yet the cells
remain sensitive to p53-dependent barriers to transformation. (A) Early-passage p162/2 MEFs were retrovirally transduced with empty (EV),
NPM-ALK- (NA), or H-Ras-V12 (Ras)-containing vectors and selected in puromycin as detailed in Fig. 1A before use in a crystal violet assay to assess
proliferative capacity. Relative cell growth was determined by comparing crystal violet optical density values obtained at 590 nm at each time point
with those obtained at day 0. Each time point was conducted in triplicate in at least 3 separate experiments using MEFs from independent embryo
preparations. Error bars are standard deviations of the mean. (B) Floxed cRblox/lox (Rb-null) or control cRblox/lox (Rb-WT) MEFs were transduced by
retrovirus with empty (EV) or NPM-ALK- (NA) containing vectors as indicated and used in 3T3 assays to assess long-term proliferative potential. The
data shown are representative of two independent cRblox/lox MEF populations derived from two different embryos. (C) Western blot analysis showing
levels of the indicated proteins in empty-vector and NPM-ALK-expressing conditional Rb-deficient (Rb-null) MEFs at late passage (cells post-senescent
at passages 18 and 15 are shown from 2 independent MEF preparation experiments). Horizontal lines on the Western blot indicate repositioning of
the gel lanes. (D) Top panel: images of the soft agarose assay (625 magnification) demonstrating that whilst NPM-ALK-expressing cells acutely
mutated for Rb have escaped senescence they do not grow in an anchorage-independent manner, and therefore are not transformed (for
NPM-ALK Induces Senescence in Primary Cells
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expressing cells due to the presence of lower levels of active p53.
Thus, p53-transcriptional targets other than p21 may be
transcribed to mediate NPM-ALK-induced senescence.
In support of a role for p53 in suppressing NPM-ALK-induced
lymphomagenesis, we observed accelerated lymphoma develop-
ment in CD2/NPM-ALK-transgenic mice expressing a single
allele of p53 (Figure 4C). Assessing the nature of the tumor-
suppressor mechanism governed by p53 in this instance of
lymphomagenesis is severely hampered by the fact that a
dysplastic, pre-tumorigenic state has not been identified in any
of the mouse models of ALCL described to date, nor in patients.
This is in contrast to the genesis of many solid tumors which can
be traced through a series of well-defined histopathological
changes in tissue architecture from a benign tumor through to
its malignant conversion. Although it remains technically chal-
lenging to identify a putative precursor cancer lesion that may
occur anywhere in the lympho-hematopoietic compartment,
senescence has been identified as an anti-tumor mechanism in
mouse models of lymphoma development driven by oncogenic
Myc or N-Ras [46,47]. Thus, identifying a role for senescence in
the suppression of NPM-ALK-driven lymphomagenesis may yet
be possible.
Germline loss of p16 is not sufficient to bypass NPM-ALK-
induced senescence; however, given the occurrence of functional
compensation by related proteins in biological systems we cannot
exclude the possibility that sporadic loss of p16 during tumor
evolution is sufficient to circumvent senescence. Nevertheless,
mutations or epigenetic modifications affecting the p16 gene are
not common in ALCL [48]. In contrast, the Rb gene is frequently
mutated or the encoded protein hyperphosphorylated (and
therefore inactive) in ALK+ ALCL [34]. Consistent with this
observation, we found that acute mutation of Rb, which mimics
sporadic mutation and limits functional compensation by the Rb-
related proteins p107 and p130, circumvents NPM-ALK-induced
senescence. We propose that loss of Rb function in the evolution of
NPM-ALK+ ALCL may be sufficient to counteract NPM-ALK-
induced activation of cell-cycle checkpoints, permitting unabated
and unchecked progress through the cell cycle. In this manner the
likelihood of acquiring additional mutations necessary for full-
blown or more aggressive malignancy, such as those affecting p53
function, may be enhanced.
Whilst MEFs do not represent the physiological target of NPM-
ALK in lymphomagenesis (indeed, the ALCL cell of origin
remains unknown), this work has highlighted the potential
existence of tumor-suppressive barriers during the development
of ALCL. Moreover, given that the transforming activity of NPM-
ALK seems to be confined to the ALK portion of the protein
through activation of the kinase domain [17], this work also raises
the possibility that p53 and/or Rb activation followed by cell-cycle
arrest may constitute a more wide-spread phenomenon in the
genesis of other cancers in which ALK is aberrantly activated. It
furthermore provides a rationale to explore senescence induction
as a potential therapeutic strategy in ALK-driven cancers.
Materials and Methods
Cells
MEFs (derived from E12.5-E13.5 embryos) and Phoenix cells
were cultured in Dulbecco’s Modified Eagles Medium (DMEM)
containing 4500 mg/L D-Glucose and 110 mg/L Sodium Pyru-
vate (Sigma-Aldrich), 10% fetal calf serum (FCS; Invitrogen,
Paisley, UK), 2 mM L-glutamine (Invitrogen) and 1% Penicillin
and Streptomycin (Gibco, Scotland, UK). MEFs were utilized at
passage 1–2. cRblox/lox and p162/2 MEFs were kindly provided by
Prof. Julien Sage (Stanford University, CA) and Prof. Pier
Giuseppe Pelicci (European Institute of Oncology, Milan, Italy)
respectively.
Antibodies
Cyclin B1 (V152) and MDM2 (ser166) antibodies were
purchased from Cell Signaling Technologies (Danvers, MA);
Cyclin A, a-tubulin and b-actin from Sigma-Aldrich (Poole, UK);
p19 (5-C3-1), p21 (F-5) and MDM2 (SMP14) from Santa Cruz
(Heidelberg, Germany); p53 (CM5) from Novocastra (Newcastle-
Table 1. Loss of p53 function is required for anchorage-
independent growth of NPM-ALK-expressing conditional Rb-
null post-senescent MEFs.
1st infection (P3)
(MSCVpuro vector)
2nd infection (P15–18)
(MSCVneo vector) Number of Foci
Empty Empty 060
Empty GSE56 060
NPM-ALK Empty 060
NPM-ALK GSE56 118611
P =passage.
doi:10.1371/journal.pone.0017854.t001
Figure 6. NPM-ALK paradoxically induces transcription and
degradation of p53 to generate an equilibrium whereby the
dominating residual levels of p53 are sufficient to induce
senescence. We propose that NPM-ALK induces transcription of p53
whilst also stabilizing MDM2 and Rb with the effect of attenuating p53
activity. However, equilibrium is reached whereby residual p53 protein
is sufficient to set in place a senescence pathway.
doi:10.1371/journal.pone.0017854.g006
quantification of data see table 1). Inactivation of p53 by GSE56 expression in these cells results in transformation (lower right box). Bottom panel:
Western blot showing NPM-ALK and p53 expression in the different cells used in the soft agarose assay. Experiments were performed twice with two
independent MEF populations. (E) p53 is induced following NPM-ALK expression in cells acutely mutated for Rb. Lysates were prepared from MEFs of
the indicated genotypes and the levels of Rb, p53, p19ARF and NPM-ALK determined by Western blot. ‘‘Rb-null’’ denotes MEFs in which the Rb gene
is acutely mutated by addition of Adenovirus expressing Cre-recombinase, and ‘‘Rb-WT’’ denotes MEFs infected with a control Cre-recombinase-
deficient Adenovirus.
doi:10.1371/journal.pone.0017854.g005
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Upon-Tyne, UK); Rb (G3-245) from BD Biosciences (Oxford,
UK); ALK from Zymed (San Francisco).
Inhibitors
MEFs were treated with 10 mM of a racemic mixture of the
MDM2 antagonists, Nutlin-3a and Nutlin-3b (Calbiochem), for
the indicated periods at 37uC/5% CO2.
Plasmids
Human NPM-ALK cDNA was cloned into the Murine Stem Cell
Virus (MSCV) puro vector. MSCVpuroK210R was generated via
site-directed mutagenesis of MSCVpuroNPM-ALK using a site-
directed mutagenesis kit (Stratagene, Cheshire, UK), following the
manufacturer’s protocol. Primer pairs K210R_Forward 59-
CCCTGCAAGTGGCTGTGAGGACGCTGCCTGAAGTGTT-
GC-39 and K210R_Reverse 59-GCAACACTTCAGGCAGCG-
TCCTCACAGCCACTTGCAGGG-39 were used. GSE56 was
cut from pL56-RAS (a gift from Dr Andrei Gudkov, Roswell Park
Cancer Institute, NY) and ligated into MSCVneo. pBabepuroH-Ras
V12 was a gift from Dr Masashi Narita (Cambridge Research
Institute, UK).
Retroviral and adenoviral infection of MEFs
Phoenix cells were transfected with the indicated plasmid
vector(s) and a murine packaging ‘‘helper’’ construct, Q, using
Fugene transfection reagent (Roche, West Sussex, UK) following
the manufacturer’s protocol. At 48 hours post-transfection, the
virus-containing media was harvested from the phoenix cells,
filtered through a 0.45 mm filter, supplemented with 4 mg/ml
polybrene (Sigma-Aldrich) and used to infect 86105–1.26106
MEFs in a 10 cm dish at 32uC/5% CO2. MEFs were selected in
2 mg/ml puromycin (Sigma-Aldrich) 48 hours post-infection for
2–3 days or 300 mg/ml geneticin (Gibco) for 7–10 days.
Adenovirus expressing recombinant Cre-recombinase from a
CMV promoter (AdCre) and insert-free adenovirus control
(AdEmpty) were purchased from the Gene Transfer Vector Core,
University of Iowa, IA. Virus (5 ml) was added to 86105–1.26106
Cre-responsive MEFs seeded into a 10 cm tissue-culture dish in
10 ml complete media, followed by incubation at 37uC/5% CO2
for 72 hours. A second round of infection was performed 16–
24 hours later.
Western blot analysis
Western blot was performed as previously described (32), using
RIPA buffer (50 mM Tris-HCl, pH 7.4; 1% NP-40; 0.25% Na-
deoxycholate; 150 mM NaCl; 0.1% Sodium dodecyl sulphate
(SDS); 1 mM Ethylenediaminetetraacetic acid (EDTA); 1 mM
Phenylmethylsulphonyl fluoride (PMSF); 2 mM Na3VO4; 20 mM
NaF; and protease inhibitor cocktail tablet (Roche)) to lyse the
cells.
Proliferation assays
Crystal violet assays were performed by seeding MEFs into 12-
well plates at a density of 2.56104 cells/well (in triplicate) which
were fixed following incubation for the indicated times with 1%
glutaraldehyde (Sigma-Aldrich) in PBS. Cells were washed with
PBS, stained with 0.1% crystal violet (Sigma-Aldrich) for
30 minutes and crystal violet extracted with 10% (v/v) acetic acid
(Sigma-Aldrich) in distilled water. The OD at 590 nm was
measured with a 1420 Multilabel VICTOR3 plate reader
(PerkinElmer, MA).
A 3T3 assay was performed according to the protocol of Todaro
and Green [49]. In brief, cells were passaged every 3 days at
1.26106 cells in 10 cm plates even in the absence of growth
between passages. If the cell number declined, cells were
maintained at an equivalent density by seeding at 36105 in a
5 cm plate or at 16105 in a 3.5 cm plate. Population doubling was
calculated using the equation:
Log Nf=Nið Þ½ =Log2
Nf is the final cell number counted after 3 days, and Ni is the initial
cell number seeded.
Apoptosis
Cells were washed twice in cold PBS followed by resuspension
in binding buffer (0.01 M 4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid [HEPES], 0.14 M NaCl and 2.5 mM CaCl2). The
cells were incubated with 5 ml APC-conjugated Annexin V
antibody (BD Biosciences) and 5 mg/ml PI at room temperature
in the dark for 15 minutes before analysis on a FACSCalibur
cytometer (BD Biosciences). Data were analyzed using FlowJo
software (TreeStar, Ashland, OR).
Cell-cycle analysis
16106 cells in 10 cm dishes were incubated with 10 mM BrdU
for 4 hours followed by fixation with 70% ice-cold ethanol/30%
PBS. Cells were washed twice in PBS, resuspended in 500 ml 2 M
HCl and incubated for 20 minutes at RT, then rinsed twice in
wash buffer (0.5% bovine serum albumin [BSA, Sigma-Aldrich] in
PBS). A 0.1 M solution of sodium borate (500 ml) (Sigma-Aldrich)
was then added followed by incubation at room temperature for
2 minutes, followed by 2 rinses in wash buffer. Cells were
resuspended in 20 ml fluorescein isothiocyanate (FITC)-conjugated
mouse anti-BrdU monoclonal antibody (BD Biosciences) and
incubated for 20 minutes in the dark. Cells were then washed
twice and resuspended in 500 ml PBS, 0.1 mg/ml RNase A
(Sigma-Aldrich), 0.4 mg/ml PI (Sigma-Aldrich) and incubated at
37uC for 30 minutes. Cells were then passed several times through
a 25-gauge needle and analyzed on a FACSCalibur cytometer (BD
Biosciences). A minimum of 20,000 events were collected per
sample and the data analyzed using FlowJo software.
SA-b-Gal assay
2.56104 cells/well of a 12-well plate (in triplicate) were fixed
with 0.5% glutaraldehyde for 15 minutes at RT. Cells were
washed twice in 1 M MgCl2 (Sigma-Aldrich) in PBS, pH5.5 and
incubated in 1 ml of X-Gal staining solution (1 mg/ml X-gal
[Sigma-Aldrich], 0.12 mM K3Fe[CN]6, 0.12 mM K4Fe[CN]6,
1 mM MgCl2 in PBS at pH5.5) overnight at 37uC. The cells were
washed 3 times in dH2O and images captured with a Leica D-
LUX 3 camera mounted onto a Labovert microscope at 6100
magnification. The percentage of cells staining positive (blue color)
for b-galactosidase activity was determined by counting the cells
by eye at640 magnification. At least 200 cells were counted per
well.
Mice
CD2/NPM-ALK transgenic mice were produced as detailed in
[30]. The p53+/2 mice were kindly provided by Prof. Terry
Rabbitts, Leeds Institute for Molecular Medicine, UK and were
bred on a C57/BL6 background. All mice were housed under spf
conditions at the University of Cambridge in accordance with UK
Home Office guidelines. The genotypes of the mice were
determined as described in [30] and [50], except that the primer
directed against the neo cassette in the latter case had the sequence
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59-TCC TCG TGC TTT ACG GTA TC-39. The Kaplan-Meier
curve and log-rank test were generated in MedCalc.
Statistical analysis
Data were analyzed using a Student’s two-tailed T test
(assuming equal variance). Data were considered significant when
p values were less than .05.
Supporting Information
Figure S1 NPM-ALK does not induce apoptosis. Annexin
V versus PI staining of day 4 primary MEFs followed by FACS
analysis demonstrates that NPM-ALK does not induce apoptosis
relative to vector-control MEFs. Results are representative of 3
independent experiments. At least 10,000 events were collected for
each genotype.
(TIF)
Figure S2 Ablation of Rb in NPM-ALK-expressing
MEFs. (A) Western Blot analysis of Rb and NPM-ALK
expression in early passage cRblox/lox MEFs infected with Cre-
recombinase-expressing (+) or Cre-recombinase-deficient Adeno-
virus (2) for 72 hours, followed by infection with vector-only or
NPM-ALK-encoding retrovirus for 48 hours. (B) Experimental
design and time-frame for assays using cRblox/lox MEFs.
(TIF)
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